Contact
Please use this form to send email to PR contact of this press release:
Synaptica Ventures Announces Publication of Groundbreaking mRNA-Based Therapy Protocol for BRCA1-Mutated Cancers
TO:
Roy Cohen
Synaptica Ventures Limited